Regeneron (REGN)
Develops antibody and genetic medicines led by Dupixent, EYLEA HD, and Libtayo.
$791.84
vs last close−12.06 (−1.50%)
Something off on this page? Send us feedback.
Next report
Oct 28, 26
in 35 days
EPS estimate
$15.99
Revenue estimate
$4.54B
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25Apr '25Aug '25Oct '25Jan '26Apr '26Jul '26Oct '26
Reported$12.07$8.22$12.89$11.83$11.44$9.47$14.29Pending
Estimate$11.21$8.62$8.43$9.65$10.74$8.91$10.16$15.99
Surprise+7.7%−4.6%+52.9%+22.6%+6.5%+6.3%+40.6%—
RevenueReportedEstimate
Feb '25Apr '25Aug '25Oct '25Jan '26Apr '26Jul '26Oct '26
Reported$3.79B$3.03B$3.68B$3.75B$3.88B$3.61B$4.29BPending
Estimate$3.74B$3.25B$3.29B$3.59B$3.81B$3.48B$3.82B$4.54B
Surprise+1.3%−6.8%+11.8%+4.5%+1.9%+3.6%+12.4%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | $17.08 | — | — |
| Sep 2027 | $16.86 | — | — |
| Jun 2027 | $15.84 | — | — |
| Mar 2027 | $11.40 | — | — |
| Dec 2026 | $15.60 | — | — |
| Oct 2026 | $15.99 | — | — |
| Jul 2026 | $10.16 | $14.29 | +40.6% |
| Apr 2026 | $8.91 | $9.47 | +6.3% |
| Jan 2026 | $10.74 | $11.44 | +6.5% |
| Oct 2025 | $9.65 | $11.83 | +22.6% |
| Aug 2025 | |||
| Apr 2025 | |||
| Feb 2025 | |||
| Oct 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | $17.08 | — | — | $4.98B | — | — | — |
| Sep 2027 | $16.86 | — | — | $4.90B | — | — | — |
| Jun 2027 | $15.84 | — | — | $4.69B | — | — | — |
| Mar 2027 | $11.40 | — | — | $3.99B | — | — | — |
| Dec 2026 | $15.60 | — | — | $4.64B | — | — | — |
| Oct 28, 2026 | $15.99 | — | — | $4.54B | — | — | — |
| Jul 30, 2026 | $10.16 | $14.29 | +40.6% | $3.82B | $4.29B | +12.4% | +6.2% |
| Apr 29, 2026 | $8.91 | $9.47 | +6.3% | $3.48B | $3.61B | +3.6% | −6.2% |
| Jan 30, 2026 | $10.74 | $11.44 | +6.5% | $3.81B | $3.88B | +1.9% | −1.1% |
| Oct 28, 2025 | $9.65 | $11.83 | +22.6% | $3.59B | $3.75B | +4.5% | +11.8% |
| Aug 1, 2025 | |||||||
| Apr 29, 2025 | |||||||
| Feb 4, 2025 | |||||||
| Oct 31, 2024 | |||||||
| Aug 1, 2024 | |||||||
| May 2, 2024 | |||||||
| Feb 2, 2024 | |||||||
| Nov 2, 2023 | |||||||
| Aug 3, 2023 | |||||||
| May 4, 2023 | |||||||
| Feb 3, 2023 | |||||||
| Nov 3, 2022 | |||||||
| Aug 3, 2022 | |||||||
| May 4, 2022 | |||||||
| Feb 4, 2022 | |||||||
| Nov 4, 2021 | |||||||
| Aug 5, 2021 | |||||||
| May 6, 2021 | |||||||
| Feb 5, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Aug 5, 2020 | |||||||
| May 5, 2020 | |||||||
| Feb 6, 2020 | |||||||
| Nov 5, 2019 | |||||||
| Aug 6, 2019 | |||||||
| May 7, 2019 | |||||||
| Feb 6, 2019 | |||||||
| Nov 6, 2018 | |||||||
| Aug 2, 2018 | |||||||
| May 3, 2018 | |||||||
| Feb 8, 2018 | |||||||
| Nov 8, 2017 | |||||||
| Aug 3, 2017 | |||||||
| May 4, 2017 | |||||||
| Feb 9, 2017 | |||||||
| Nov 4, 2016 | |||||||
| Aug 4, 2016 | |||||||
| May 5, 2016 | |||||||
| Feb 9, 2016 | |||||||
| Nov 4, 2015 | |||||||
| Aug 4, 2015 |